ReviewStroke (Hoboken, N.J.)2021
Therapeutic Advancements in the Endovascular Management of Acute Ischemic Stroke.
Review in Stroke (Hoboken, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Imaging in acute ischaemic stroke: assessing findings in light of evolving therapies.The British journal of radiology · 2024Review
- Mechanical Thrombectomy in the Late Presentation of Anterior Circulation Large Vessel Occlusion Stroke: A Guideline From the Society of Vascular and Interventional Neurology Guidelines and Practice Standards Committee.Stroke (Hoboken, N.J.) · 2023Article
- Current State of Stroke Care in Vietnam.Stroke (Hoboken, N.J.) · 2022Article
- Impacts of stress hyperglycemia ratio on functional outcomes of ischemic stroke patients treated with intravenous thrombolysis: a population-based study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is the major cause of disability and the second leading cause of death worldwide. Acute ischemic stroke is responsible for ∼85% of all strokes, with 24% to 46% attributable to large-vessel occlusion, which are typically associated with worse outcomes. Although the initial efforts to develop endovascular treatment for acute ischemic stroke took place over 6 decades ago, critical gaps in device technology and treatment selection existed, resulting in 3 failed randomized clinical trials published in 2013. Fortunately, devices and techniques have dramatically evolved over the past decade, leading to significant improvements in the safety, speed, and completeness of reperfusion. Since 2015, a total of 9 randomized trials have consistently demonstrated an overwhelming benefit to endovascular reperfusion. In this article, we will review the evolution of endovascular treatment for acute ischemic stroke, including the technical and technological advances as well as the perspectives in terms of patient selection and procedural and clinical outcomes of the landmark past and recent trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.